Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial looked at a medicine called MORF-057 in people with ulcerative colitis, a condition that causes inflammation in the large bowel. A total of 280 people took part, split across four groups: one group took MORF-057 at 200 mg twice daily, one took 100 mg twice daily, one took 100 mg once daily in the morning, and one took a placebo (a dummy pill with no active ingredient). The trial's main goal was to measure how many participants reached "clinical remission" — meaning their bowel symptoms and a camera examination of the bowel (endoscopy) both showed very low levels of disease activity — using a standard scoring tool called the Modified Mayo Clinic Score. The reported data shows that, for the primary goal of clinical remission at the end of the study, 31.9% of participants in the 200 mg twice-daily group, 23.9% in the 100 mg twice-daily group, and 17.1% in the 100 mg once-daily group met that definition. In the placebo group, 24.3% of participants also met the remission definition. For a secondary measure — "clinical response," meaning a meaningful improvement in symptoms and endoscopy score compared to the start of the trial — the reported figures were 62.3% for the 200 mg twice-daily group, 53.5% for the 100 mg twice-daily group, 57.1% for the 100 mg once-daily group, and 54.3% for the placebo group. No other outcome data was included in the structured results submitted. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Crohn's Disease and Colitis Trial, Active, Not Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have had moderate to severe ulcerative colitis (UC) symptoms for at least 3 months before the screening visit.
- Your UC affects a large enough portion of your colon (reaching at least 15 cm from the opening of the rectum).
- You have tried at least one UC treatment in the past — such as aminosalicylates (e.g., mesalamine), steroids, immune-suppressing drugs (e.g., azathioprine), or advanced treatments like biologics or JAK inhibitors — and it either did not work well enough, stopped working, or you could not tolerate it.
- You have never previously been treated with a type of medication called an "anti-integrin therapy" (either approved or experimental).
- You are willing and able to follow all study rules and requirements.
- You are able to give your signed, informed consent to take part.
Who may not be able to join:
- You have been diagnosed with a different type of colitis or bowel condition, such as Crohn's disease, microscopic colitis, ischemic colitis, or radiation colitis, or you have symptoms that may suggest Crohn's disease.
- You show positive results on a questionnaire used to screen for neurological (nerve or brain-related) symptoms.
- You have another serious or unstable health condition occurring at the same time.
- You have previously been treated with vedolizumab or any other approved or experimental integrin-blocking medication.
- You are currently in another clinical trial or have received an experimental treatment within the last 30 days.
- You have previously been given the study drug MORF-057, or you have a known allergy or sensitivity to drugs that work in a similar way.
- You are unable to attend study appointments or follow the study procedures.
⚠️ Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
5 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percentage of Participants in Clinical Remission as Determined Using the Modified Mayo Clinic Score (mMCS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.